REMARKS

Claims 1-2, 5-7, 9-13, 15-16, and 18 are all the claims pending in the application. Claims 5 and 10 have been amended to correct the spelling of "indan".

Entry of the above amendments is respectfully requested.

The Examiner has indicated in the Advisory Action of August 25, 2009 that claims 1-2, 5-7, 9-13, 15 and 18 are allowed.

However, the Examiner maintains the rejection of claim 16 under 35 U.S.C. § 112, first paragraph, as allegedly because the specification does not reasonably provide enablement for treatment of the claimed disorders.

The Examiner notes that the specification provides minimal guidance and because of uncertainty in the art, with respect to the use of compounds of the entire genus of formula (1).

Applicants respectfully traverse.

Claim 16 recites "A method for treatment of urinary system disease selected from the group consisting of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof", and thus the disease in claim 16 is limited to specific diseases.

The Examiner refers to Kubinyi in support of his position that the art is highly unpredictable, however the portion of Kubinyi provided and relied upon by the Examiner relates to multiple binding modes and certain aspects of inhibitor binding. In addition, since the compounds in the present application are not enzyme inhibitors and are compounds antagonizing

EDG-2 which is a LPA receptor, Applicants submit that it is inappropriate to reject the claims in the present application based on Kubinyi which relates to enzyme inhibitors. Thus, Kubinyi is not particularly relevant to the present case and/or is insufficient to rebut the discussion of the prior art in the present specification of compounds having some general structural similarity to the claimed compounds which were previously known to possess LPA and/or EDG-2 inhibitory activity.

Additionally, Applicants submit that the present specification provides *in vivo* data showing that a compound within the scope of the present claims has an effect on urethral pressure, which can be reasonably correlated to the claimed method of treatment and other compounds within the scope of the present claims.

It is publicly known from US 7,288,558 that compounds having EDG-2 antagonistic activity are effective for treatment of urinary system diseases, especially pollakiuria and dysuria. Therefore, since the compounds in the present application have EDG-2 antagonistic activity as described above, it is clear that the compounds in the present application are effective for specific urinary system diseases recited in present claim 16 and that present invention enables the person skilled in the art to use the present invention.

Accordingly, Applicants respectfully request withdrawal of the rejection under 35 U.S.C. § 112, 1st paragraph, for lack of enablement.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited.

If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: September 11, 2009